- Home
- KOD vs ERAS Comparison
KOD vs ERAS Comparison
Compare KOD & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- ERAS
- Stock Information
- Founded
- KOD 2009
- ERAS 2018
- Country
- KOD United States
- ERAS United States
- Employees
- KOD N/A
- ERAS N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- ERAS Health Care
- Exchange
- KOD Nasdaq
- ERAS Nasdaq
- Market Cap
- KOD 454.7M
- ERAS 432.6M
- IPO Year
- KOD 2018
- ERAS 2021
- Fundamental
- Price
- KOD $3.45
- ERAS $1.47
- Analyst Decision
- KOD Hold
- ERAS Strong Buy
- Analyst Count
- KOD 4
- ERAS 6
- Target Price
- KOD $8.00
- ERAS $5.42
- AVG Volume (30 Days)
- KOD 306.7K
- ERAS 1.3M
- Earning Date
- KOD 03-27-2025
- ERAS 05-07-2025
- Dividend Yield
- KOD N/A
- ERAS N/A
- EPS Growth
- KOD N/A
- ERAS N/A
- EPS
- KOD N/A
- ERAS N/A
- Revenue
- KOD N/A
- ERAS N/A
- Revenue This Year
- KOD N/A
- ERAS N/A
- Revenue Next Year
- KOD N/A
- ERAS N/A
- P/E Ratio
- KOD N/A
- ERAS N/A
- Revenue Growth
- KOD N/A
- ERAS N/A
- 52 Week Low
- KOD $2.19
- ERAS $1.23
- 52 Week High
- KOD $11.60
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- KOD 28.84
- ERAS 44.42
- Support Level
- KOD $3.59
- ERAS $1.23
- Resistance Level
- KOD $3.89
- ERAS $1.59
- Average True Range (ATR)
- KOD 0.35
- ERAS 0.13
- MACD
- KOD 0.07
- ERAS 0.04
- Stochastic Oscillator
- KOD 4.98
- ERAS 67.61
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.